ImmuCell Corporation
ICCC Healthcare Biotechnology
ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024. In the quarter to June 2026, revenue grew 11.5%, EPS grew 233.3%, free cash flow grew 54.9% and total debt fell 15.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ICCC
ImmuCell Corporation (ICCC) EV/Sales
As of 16 October 2026, ImmuCell Corporation (ICCC) trades at a EV/Sales of 3.1×. Over the past ten years it has ranged from 1.4× (November 2016) to 5.7× (February 2021); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | 19.31% |
| FY2024 | 1.8× | (35.23%) |
| FY2023 | 2.8× | (3.25%) |
| FY2022 | 2.9× | (5.15%) |
| FY2021 | 3.1× | 7.02% |
| FY2020 | 2.9× | 14.41% |
| FY2019 | 2.5× | (39.39%) |
| FY2018 | 4.2× | (5.39%) |
| FY2017 | 4.4× | 140.50% |
| FY2016 | 1.8× | (6.43%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.0× | 49.38% |
| Mar 2026 | 2.0× | (10.16%) |
| Dec 2025 | 2.2× | (1.71%) |
| Sep 2025 | 2.2× | (5.08%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MIST Milestone Pharmaceuticals Inc. compare | −2.4× |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| ICCC ImmuCell Corporation | 3.1× |
| NRXS Neuraxis, Inc. compare | 16.0× |
| RANI Rani Therapeutics Holdings, Inc. compare | 16.3× |
| CBUS Cibus, Inc. compare | 18.9× |
| ATRA Atara Biotherapeutics, Inc. compare | 20.7× |
| ANIX ANIXA BIOSCIENCES INC compare | 83.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)